免疫毒素和抗体药物偶联物治疗血液系统恶性肿瘤。
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
机构信息
Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA.
出版信息
Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374.
Abstract
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
摘要
为了使抗体能够发挥细胞毒性抗癌作用，可以通过与蛋白毒素或高活性、低分子量药物结合进行修饰。这些分子分别被称为免疫毒素和抗体药物偶联物，代表了抗体介导的癌症治疗的第二次革命。因此，根据抗体对细胞表面靶抗原的特异性，将高毒性化合物递送到癌细胞内部。
相似文献
1
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.免疫毒素和抗体药物偶联物治疗血液系统恶性肿瘤。
Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374.
2
Cancer-homing toxins.癌症归巢毒素
Curr Pharm Des. 2002;8(22):1973-85. doi: 10.2174/1381612023393477.
3
Immunotoxins for leukemia.免疫毒素治疗白血病。
Blood. 2014 Apr 17;123(16):2470-7. doi: 10.1182/blood-2014-01-492256. Epub 2014 Feb 27.
4
Immunotoxins in the treatment of refractory hairy cell leukemia.免疫毒素治疗难治性毛细胞白血病
Hematol Oncol Clin North Am. 2006 Oct;20(5):1137-51, viii. doi: 10.1016/j.hoc.2006.06.009.
5
Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.急性髓系白血病的细胞表面受体靶向治疗：综述
Cancer Biother Radiopharm. 2000 Oct;15(5):459-76. doi: 10.1089/cbr.2000.15.459.
6
Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates.用于制备单体抗体-卡奇霉素缀合物的反应添加剂的选择。
Bioconjug Chem. 2008 Jan;19(1):358-61. doi: 10.1021/bc700321z. Epub 2007 Nov 10.
7
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.一种用于治疗急性髓系白血病的抗CD33抗体-卡奇霉素偶联物。连接子的选择。
Bioconjug Chem. 2002 Jan-Feb;13(1):40-6. doi: 10.1021/bc0100206.
8
Recombinant immunotoxins for treating cancer.用于治疗癌症的重组免疫毒素。
Int J Med Microbiol. 2004 Apr;293(7-8):577-82. doi: 10.1078/1438-4221-00302.
9
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.CAT-8015：一种基于第二代铜绿假单胞菌外毒素A的免疫疗法，靶向表达CD22的血液系统恶性肿瘤。
Clin Cancer Res. 2009 Feb 1;15(3):832-9. doi: 10.1158/1078-0432.CCR-08-1456.
10
Immunotoxins in the treatment of hematologic malignancies.免疫毒素在血液系统恶性肿瘤治疗中的应用
Curr Drug Targets. 2006 Oct;7(10):1301-11. doi: 10.2174/138945006778559139.
引用本文的文献
1
Amplification of Signal on Cell Surfaces in Molecular Cascades.分子级联反应中细胞表面信号的放大。
Cells. 2023 Dec 18;12(24):2858. doi: 10.3390/cells12242858.
2
Targeting CD22 for B-cell hematologic malignancies.以CD22为靶点治疗B细胞血液系统恶性肿瘤。
Exp Hematol Oncol. 2023 Oct 11;12(1):90. doi: 10.1186/s40164-023-00454-7.
3
Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.曲妥珠单抗与肿瘤结合的瞬时抑制作用以克服“结合位障碍”并提高曲妥珠单抗-蓖麻毒素免疫毒素的疗效。
Mol Cancer Ther. 2022 Oct 7;21(10):1573-1582. doi: 10.1158/1535-7163.MCT-22-0192.
4
Recombinant immunotoxins development for HER2-based targeted cancer therapies.用于基于HER2的靶向癌症治疗的重组免疫毒素研发。
Cancer Cell Int. 2021 Sep 6;21(1):470. doi: 10.1186/s12935-021-02182-6.
5
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.成像引导治疗：曲妥珠单抗和EpCAM导向毒素同时靶向HER2和EpCAM在卵巢癌模型中具有相加作用
Cancers (Basel). 2021 Aug 4;13(16):3939. doi: 10.3390/cancers13163939.
6
Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.天然与设计毒素用于精准治疗：实验肿瘤学的现代方法。
Int J Mol Sci. 2021 May 7;22(9):4975. doi: 10.3390/ijms22094975.
7
Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells.适配体驱动的毒素基因在U87模型胶质母细胞瘤细胞中的递送
Front Pharmacol. 2021 Apr 15;12:588306. doi: 10.3389/fphar.2021.588306. eCollection 2021.
8
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病的挑战与临床策略：综述与进展
Front Immunol. 2021 Feb 10;11:569117. doi: 10.3389/fimmu.2020.569117. eCollection 2020.
9
Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells.靶向GPC3的重组免疫毒素对H446小细胞肺癌细胞具有细胞毒性。
Oncol Lett. 2021 Mar;21(3):222. doi: 10.3892/ol.2021.12483. Epub 2021 Jan 21.
10
Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma.磷脂酰肌醇蛋白聚糖-3：一种用于肝细胞癌检测与治疗的分子标志物。
Liver Res. 2020 Dec;4(4):168-172. doi: 10.1016/j.livres.2020.11.003. Epub 2020 Nov 11.
本文引用的文献
1
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.一项抗 CD19 美登素免疫偶联物 SAR3419 的 I 期多剂量递增研究，该药物通过静脉输注给药，每 3 周给药一次，用于治疗复发/难治性 B 细胞淋巴瘤患者。
J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2.
2
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
3
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.本妥昔单抗维迪昔（SGN-35）治疗复发性 CD30 阳性淋巴瘤。
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.
4
Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.抗CD3白喉免疫毒素在CD3阳性T细胞淋巴瘤试验中的药理学
Methods Mol Biol. 2010;651:157-75. doi: 10.1007/978-1-60761-786-0_10.
5
Antibody-drug conjugates: targeted drug delivery for cancer.抗体药物偶联物：癌症的靶向药物递送。
Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17.
6
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.通过引入肿瘤特异性嵌合抗原受体来改变 T 细胞的特异性。
Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3.
7
Monoclonal antibodies: versatile platforms for cancer immunotherapy.单克隆抗体：癌症免疫治疗的多面平台。
Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744.
8
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.安全、药代动力学和新型免疫偶联药物奥滨尤妥珠单抗治疗 B 细胞非霍奇金淋巴瘤的初步临床活性：一项 I 期研究结果。
J Clin Oncol. 2010 Apr 20;28(12):2085-93. doi: 10.1200/JCO.2009.25.1900. Epub 2010 Mar 22.
9
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.用于儿童 CD22 阳性血液系统恶性肿瘤的抗 CD22 免疫毒素 RFB4(dsFv)-PE38 (BL22)：临床前研究和 I 期临床试验。
Clin Cancer Res. 2010 Mar 15;16(6):1894-903. doi: 10.1158/1078-0432.CCR-09-2980. Epub 2010 Mar 9.
10
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.三期安慰剂对照临床试验：探讨 denileukin diftitox 在皮肤 T 细胞淋巴瘤患者中的应用。
J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.
Zotero 插件